Based on existing studies, combining SphK inhibitors with anti-TNF therapies, through dual targeting of intrinsic apoptotic resistance and the immunosuppressive microenvironment in HCC cells, offers a new strategy to overcome treatment resistance. This evidence concerns the gene TNF and hepatocellular carcinoma.